Deterministic generation of remote entanglement with active quantum feedback

We consider the task of deterministically entangling two remote qubits using joint measurement and feedback, but no directly entangling Hamiltonian. In order to formulate the most effective experimentally feasible protocol, we introduce the notion of average-sense locally optimal feedback protocols, which do not require real-time quantum state estimation, a difficult component of real-time quantum feedback control. We use this notion of optimality to construct two protocols that can deterministically create maximal entanglement: a semiclassical feedback protocol for low-efficiency measurements and a quantum feedback protocol for high-efficiency measurements. The latter reduces to direct feedback in the continuous-time limit, whose dynamics can be modeled by a Wiseman-Milburn feedback master equation, which yields an analytic solution in the limit of unit measurement efficiency. Our formalism can smoothly interpolate between continuous-time and discrete-time descriptions of feedback dynamics and we exploit this feature to derive a superior hybrid protocol for arbitrary nonunit measurement efficiency that switches between quantum and semiclassical protocols. Finally, we show using simulations incorporating experimental imperfections that deterministic entanglement of remote superconducting qubits may be achieved with current technology using the continuous-time feedback protocol alone

Dimension Spectra of Lines

This paper investigates the algorithmic dimension spectra of lines in the Euclidean plane. Given any line L with slope a and vertical intercept b, the dimension spectrum sp(L) is the set of all effective Hausdorff dimensions of individual points on L. We draw on Kolmogorov complexity and geometrical arguments to show that if the effective Hausdorff dimension dim(a, b) is equal to the effective packing dimension Dim(a, b), then sp(L) contains a unit interval. We also show that, if the dimension dim(a, b) is at least one, then sp(L) is infinite. Together with previous work, this implies that the dimension spectrum of any line is infinite

An analysis on reasons of non-compliant to cardiac rehabilitation programme

Abstract no. 09published_or_final_versio

Molecular characters and recombinant expression of the carboxylesterase gene of the meadow moth Loxostege sticticalis L. (Lepidoptera: Pyralidae)

Insect carboxylesterases are enzymes that catalyze the hydrolysis of ester and amide moieties, which play important roles in insecticide resistance, specifically allelochemical tolerance and developmental regulation. We obtained the cDNA encoding carboxylesterase gene of Loxostege sticticalis (LstiCarE) by a cDNA library screen. The full cDNA of LstiCarE is 1,980 bp in length, containing an open reading frame (ORF) of 1,875 bp, which encodes a preprotein of 625 amino acid residues. The LstiCarE contains the catalytic triad (Ser-His-Glu), the pentapeptide GxSxG motif and GxxHxxD/E motif, which are typical characteristic of esterases. The GxSxG and GxxHxxD/E motifs of LstiCarE are modified as GCSAG and GxxHxxQ, respectively. The 3-D model structure of LstiCarE showed that Ser197, His440 and Glu321 are aggregated together, which form the catalytic triad. The recombinant LstiCarE were successfully expressed in BL21 cells using recombinant plasmid DNA, and showed high carboxylesterase activity. However, the biochemical and physiological functions of carboxylesterase gene in L. sticticalis requires further investigation.Key words: Carboxylesterase gene, Loxostege sticticalis, recombinant expression

Influence of clinical parameters on short-term outcome in cardiac rehabilitation patients after actue myocardial infarction

published_or_final_versio

Cardiac rehabilitation improves functional and clinical status of patients after AMI or PTCA - a randomised controlled study

published_or_final_versio

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

Background: Psoriasis symptoms have a significant negative impact on health-related quality of life, impairing physical functioning and well-being. Objective: To evaluate the impact of brodalumab, a human anti-interleukin-17R monoclonal antibody, on psoriasis symptom severity as measured by a novel patient-reported outcome measure, the Psoriasis Symptom Inventory, and dermatology-specific health-related quality of life as measured by the Dermatology Life Quality Index (DLQI). Methods: This was a secondary analysis of a phase II, randomized, double-blind, placebo-controlled clinical study of patients with moderate-to-severe psoriasis (n = 198) treated with brodalumab or placebo. This analysis assessed Psoriasis Symptom Inventory scores and DLQI scores over time. Analyses were conducted on all patients who were randomized and received one or more injections of the study drug according to intention to treat using last observation carried forward to impute missing data. Results: At week 12, subjects in the brodalumab groups had significant improvements in mean Psoriasis Symptom Inventory total scores [8·5 (70 mg), 15·8 (140 mg), 16·2 (210 mg) and 12·7 (280 mg)] compared with placebo (4·8). Mean improvements in DLQI were clinically meaningful (≥ 5·7) in the brodalumab groups (6·2, 9·1, 9·6 and 7·1, respectively) and significantly greater than placebo (3·1). Improvements in Psoriasis Symptom Inventory were observed as early as week 2 and in DLQI by week 4. All eight Psoriasis Symptom Inventory item scores improved significantly among the brodalumab groups by week 12. Conclusions: Results were from a single randomized clinical trial and may not generalize to broader patient populations. However, treatment with brodalumab provided significant improvement in psoriasis symptoms in patients with moderate-to-severe psoriasis